{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:51:18Z","timestamp":1790009478798,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1038\/s41440-023-01238-6","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T21:03:21Z","timestamp":1677618201000},"page":"1168-1170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Visceral fat: a bad companion for mineralocorticoid receptor overactivation"],"prefix":"10.1038","volume":"46","author":[{"given":"Yuichi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"1238_CR1","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/sj.ijo.0803642","volume":"31","author":"AW Krug","year":"2007","unstructured":"Krug AW, Vleugels K, Schinner S, Lamounier-Zepter V, Ziegler CG, Bornstein SR, et al. Human adipocytes induce an ERK1\/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. Int J Obes (Lond). 2007;31:1605\u201316.","journal-title":"Int J Obes (Lond)"},{"key":"1238_CR2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323.","journal-title":"Am J Hypertens"},{"key":"1238_CR3","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/en.2003-1336","volume":"145","author":"JN Fain","year":"2004","unstructured":"Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273\u201382.","journal-title":"Endocrinology"},{"key":"1238_CR4","doi-asserted-by":"publisher","unstructured":"Haze T, Ozawa M, Kawano R, Haruna A, Ohki Y, Suzuki S, et al. Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism. Hypertens Res. https:\/\/doi.org\/10.1038\/s41440-023-01170-9 (2023).","DOI":"10.1038\/s41440-023-01170-9"},{"key":"1238_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41440-021-00719-w","volume":"44","author":"T Haze","year":"2021","unstructured":"Haze T, Hatakeyama M, Komiya S, Kawano R, Ohki Y, Suzuki S, et al. Association of the ratio of visceral-to-subcutaneous fat volume with renal function among patients with primary aldosteronism. Hypertens Res. 2021;44:1341\u201351.","journal-title":"Hypertens Res"},{"key":"1238_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/jhh.2010.65","volume":"24","author":"Z Soml\u00f3ov\u00e1","year":"2010","unstructured":"Soml\u00f3ov\u00e1 Z, Widimsk\u00fd J Jr., Rosa J, Wichterle D, Strauch B, Petr\u00e1k O, et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens. 2010;24:625\u201330.","journal-title":"J Hum Hypertens"},{"key":"1238_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41440-022-00967-4","volume":"45","author":"M Mogi","year":"2022","unstructured":"Mogi M, Maruhashi T, Higashi Y, Masuda T, Nagata D, Nagai M, et al. Update on Hypertension Research in 2021. Hypertens Res. 2022;45:1276\u201397.","journal-title":"Hypertens Res"},{"key":"1238_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460\u201370.","journal-title":"Circulation."},{"key":"1238_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jacc.2021.07.049","volume":"78","author":"M Bohm","year":"2021","unstructured":"Bohm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure. J Am Coll Cardiol. 2021;78:1337\u201348.","journal-title":"J Am Coll Cardiol"},{"key":"1238_CR10","doi-asserted-by":"publisher","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","volume":"17","author":"R Pan","year":"2022","unstructured":"Pan R, Zhang Y, Wang R, Xu Y, Ji H, Zhao Y. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. PLoS One. 2022;17:e0279889.","journal-title":"PLoS One"},{"key":"1238_CR11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/oby.22443","volume":"27","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y, Gotoh K, Masaki T, Ozeki Y, Tokoro M, Kudo A, et al. Effects of sleeve gastrectomy on blood pressure and the renal renin-angiotensin system in rats with diet-induced obesity. Obes (Silver Spring). 2019;27:785\u201392.","journal-title":"Obes (Silver Spring)"},{"key":"1238_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1238_CR13","doi-asserted-by":"crossref","unstructured":"Yoshida Y, Fujiki R, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, et al. Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels. Hypertens Res. 2023;46:100\u20137.","DOI":"10.1038\/s41440-022-01045-5"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01238-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01238-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01238-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T19:22:49Z","timestamp":1701976969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01238-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1038\/s41440-023-01238-6","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"28 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HS has honorarium from Daiichi-Sankyo Company, Mochida Pharmaceuticals, Astrazeneca, Novartis Pharma, Bayer, and Astellas. HS also received scholarship from Chugai and Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}